AstraZeneca continues pursuit of treating overlapping diseases

11 April 2019

AstraZeneca (LSE: AZN) continues to make strides in the company’s vision to advance clinical practice from treating patients with a single disease, such as type-2 diabetes (T2D), to addressing overlapping disease areas and risk factors, such as kidney disease.

This coming weekend, findings will be presented at the ISN-World Congress of Nephrology (WCN), which continue to reveal how two of the Anglo-Swedish pharma major’s medicines are demonstrating compelling new evidence that may translate to the clinical practice.

Specifically, in the AstraZeneca DELIGHT trial, Forxiga (dapagliflozin) alone and in combination with saxagliptin, demonstrated significant reductions in urine albumin-to-creatinine ratio (UACR) compared to placebo in patients with T2D and chronic kidney disease (CKD).

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK